AAPL333.33+3.01 (+0.91%) ▲|ABBV261.41+1.48 (+0.57%) ▲|ABT97.12+0.43 (+0.44%) ▲|ACN200.00-12.30 (-5.79%) ▼|ADBE237.53-3.75 (-1.55%) ▼|AMAT538.00+8.70 (+1.64%) ▲|AMD631.89+16.16 (+2.62%) ▲|AMGN403.41-3.86 (-0.95%) ▼|AMT163.07+2.01 (+1.25%) ▲|AMZN251.13+2.90 (+1.17%) ▲|AVGO353.27+9.63 (+2.80%) ▲|AXP303.12+1.03 (+0.34%) ▲|BA193.56+1.28 (+0.66%) ▲|BAC53.60-0.14 (-0.25%) ▼|BKNG159.66-0.62 (-0.39%) ▼|BLK1,070.05+5.69 (+0.53%) ▲|BMY60.90+0.07 (+0.12%) ▲|BNY145.43+1.51 (+1.05%) ▲|BRK-B502.66+2.16 (+0.43%) ▲|C128.13+1.13 (+0.89%) ▲|CAT848.56+22.21 (+2.69%) ▲|CL84.32-0.22 (-0.25%) ▼|CMCSA21.55-0.16 (-0.71%) ▼|COF195.56+1.08 (+0.55%) ▲|COP126.80-0.26 (-0.20%) ▼|COST915.62+0.68 (+0.07%) ▲|CRM233.87-2.82 (-1.19%) ▼|CSCO111.81+3.47 (+3.20%) ▲|CVS86.09+0.89 (+1.04%) ▲|CVX206.92-0.18 (-0.09%) ▼|DE679.44+12.18 (+1.83%) ▲|DHR215.00+3.24 (+1.53%) ▲|DIS102.37+1.04 (+1.03%) ▲|DUK113.97+0.23 (+0.20%) ▲|EMR161.45+2.88 (+1.82%) ▲|FDX288.91+1.84 (+0.64%) ▲|GD329.69-3.04 (-0.91%) ▼|GE311.92-0.47 (-0.15%) ▼|GEV992.82+5.37 (+0.54%) ▲|GILD144.59-2.92 (-1.98%) ▼|GM78.72-0.59 (-0.74%) ▼|GOOG340.84+5.91 (+1.76%) ▲|GOOGL343.89+5.65 (+1.67%) ▲|GS902.09+5.42 (+0.60%) ▲|HD283.74+1.28 (+0.45%) ▲|HON214.43+0.63 (+0.29%) ▲|IBM222.32-3.30 (-1.46%) ▼|INTC120.26+0.26 (+0.22%) ▲|INTU280.01-2.78 (-0.98%) ▼|ISRG395.16-6.08 (-1.52%) ▼|JNJ256.34-2.32 (-0.90%) ▼|JPM331.17-2.02 (-0.60%) ▼|KO85.62-0.48 (-0.56%) ▼|LIN477.43+7.98 (+1.70%) ▲|LLY1,142.60-7.25 (-0.63%) ▼|LMT505.25-0.25 (-0.05%) ▼|LOW181.60-0.78 (-0.43%) ▼|LRCX348.58+8.48 (+2.49%) ▲|MA554.48+4.48 (+0.81%) ▲|MCD232.10+0.27 (+0.12%) ▲|MDLZ58.10+0.34 (+0.58%) ▲|MDT86.48+0.04 (+0.05%) ▲|META728.19+2.26 (+0.31%) ▲|MMM162.26-0.76 (-0.47%) ▼|MO67.22+0.27 (+0.40%) ▲|MRK143.70-0.12 (-0.08%) ▼|MS190.71+2.70 (+1.44%) ▲|MSFT514.54+1.74 (+0.34%) ▲|MU1,077.91-19.48 (-1.78%) ▼|NEE76.80+0.45 (+0.58%) ▲|NFLX67.03-0.83 (-1.22%) ▼|NKE33.54-1.61 (-4.58%) ▼|NOW135.32-2.44 (-1.77%) ▼|NVDA234.62+3.76 (+1.63%) ▲|ORCL141.13+3.06 (+2.21%) ▲|PEP125.47-0.13 (-0.10%) ▼|PFE27.60-0.52 (-1.85%) ▼|PG144.50+0.55 (+0.38%) ▲|PLTR189.20-0.84 (-0.44%) ▼|PM187.27+0.69 (+0.37%) ▲|QCOM185.44+3.35 (+1.84%) ▲|RTX185.10+0.09 (+0.05%) ▲|SBUX94.66-0.22 (-0.23%) ▼|SCHW97.05-1.33 (-1.35%) ▼|SO83.67+0.20 (+0.23%) ▲|SPG200.86+0.05 (+0.02%) ▲|T24.31+0.01 (+0.02%) ▲|TMO653.64+1.13 (+0.17%) ▲|TMUS164.02+2.29 (+1.41%) ▲|TSLA372.15+18.04 (+5.09%) ▲|TXN293.57+12.26 (+4.36%) ▲|UBER68.09+0.21 (+0.31%) ▲|UNH369.92+4.72 (+1.29%) ▲|UNP277.47+5.05 (+1.85%) ▲|UPS93.22-0.67 (-0.71%) ▼|USB57.54+0.18 (+0.31%) ▲|V360.65+0.80 (+0.22%) ▲|VZ45.95-0.03 (-0.07%) ▼|WFC80.28+0.03 (+0.04%) ▲|WMT104.20-0.07 (-0.06%) ▼|XOM164.35+0.53 (+0.32%) ▲|AAPL333.33+3.01 (+0.91%) ▲|ABBV261.41+1.48 (+0.57%) ▲|ABT97.12+0.43 (+0.44%) ▲|ACN200.00-12.30 (-5.79%) ▼|ADBE237.53-3.75 (-1.55%) ▼|AMAT538.00+8.70 (+1.64%) ▲|AMD631.89+16.16 (+2.62%) ▲|AMGN403.41-3.86 (-0.95%) ▼|AMT163.07+2.01 (+1.25%) ▲|AMZN251.13+2.90 (+1.17%) ▲|AVGO353.27+9.63 (+2.80%) ▲|AXP303.12+1.03 (+0.34%) ▲|BA193.56+1.28 (+0.66%) ▲|BAC53.60-0.14 (-0.25%) ▼|BKNG159.66-0.62 (-0.39%) ▼|BLK1,070.05+5.69 (+0.53%) ▲|BMY60.90+0.07 (+0.12%) ▲|BNY145.43+1.51 (+1.05%) ▲|BRK-B502.66+2.16 (+0.43%) ▲|C128.13+1.13 (+0.89%) ▲|CAT848.56+22.21 (+2.69%) ▲|CL84.32-0.22 (-0.25%) ▼|CMCSA21.55-0.16 (-0.71%) ▼|COF195.56+1.08 (+0.55%) ▲|COP126.80-0.26 (-0.20%) ▼|COST915.62+0.68 (+0.07%) ▲|CRM233.87-2.82 (-1.19%) ▼|CSCO111.81+3.47 (+3.20%) ▲|CVS86.09+0.89 (+1.04%) ▲|CVX206.92-0.18 (-0.09%) ▼|DE679.44+12.18 (+1.83%) ▲|DHR215.00+3.24 (+1.53%) ▲|DIS102.37+1.04 (+1.03%) ▲|DUK113.97+0.23 (+0.20%) ▲|EMR161.45+2.88 (+1.82%) ▲|FDX288.91+1.84 (+0.64%) ▲|GD329.69-3.04 (-0.91%) ▼|GE311.92-0.47 (-0.15%) ▼|GEV992.82+5.37 (+0.54%) ▲|GILD144.59-2.92 (-1.98%) ▼|GM78.72-0.59 (-0.74%) ▼|GOOG340.84+5.91 (+1.76%) ▲|GOOGL343.89+5.65 (+1.67%) ▲|GS902.09+5.42 (+0.60%) ▲|HD283.74+1.28 (+0.45%) ▲|HON214.43+0.63 (+0.29%) ▲|IBM222.32-3.30 (-1.46%) ▼|INTC120.26+0.26 (+0.22%) ▲|INTU280.01-2.78 (-0.98%) ▼|ISRG395.16-6.08 (-1.52%) ▼|JNJ256.34-2.32 (-0.90%) ▼|JPM331.17-2.02 (-0.60%) ▼|KO85.62-0.48 (-0.56%) ▼|LIN477.43+7.98 (+1.70%) ▲|LLY1,142.60-7.25 (-0.63%) ▼|LMT505.25-0.25 (-0.05%) ▼|LOW181.60-0.78 (-0.43%) ▼|LRCX348.58+8.48 (+2.49%) ▲|MA554.48+4.48 (+0.81%) ▲|MCD232.10+0.27 (+0.12%) ▲|MDLZ58.10+0.34 (+0.58%) ▲|MDT86.48+0.04 (+0.05%) ▲|META728.19+2.26 (+0.31%) ▲|MMM162.26-0.76 (-0.47%) ▼|MO67.22+0.27 (+0.40%) ▲|MRK143.70-0.12 (-0.08%) ▼|MS190.71+2.70 (+1.44%) ▲|MSFT514.54+1.74 (+0.34%) ▲|MU1,077.91-19.48 (-1.78%) ▼|NEE76.80+0.45 (+0.58%) ▲|NFLX67.03-0.83 (-1.22%) ▼|NKE33.54-1.61 (-4.58%) ▼|NOW135.32-2.44 (-1.77%) ▼|NVDA234.62+3.76 (+1.63%) ▲|ORCL141.13+3.06 (+2.21%) ▲|PEP125.47-0.13 (-0.10%) ▼|PFE27.60-0.52 (-1.85%) ▼|PG144.50+0.55 (+0.38%) ▲|PLTR189.20-0.84 (-0.44%) ▼|PM187.27+0.69 (+0.37%) ▲|QCOM185.44+3.35 (+1.84%) ▲|RTX185.10+0.09 (+0.05%) ▲|SBUX94.66-0.22 (-0.23%) ▼|SCHW97.05-1.33 (-1.35%) ▼|SO83.67+0.20 (+0.23%) ▲|SPG200.86+0.05 (+0.02%) ▲|T24.31+0.01 (+0.02%) ▲|TMO653.64+1.13 (+0.17%) ▲|TMUS164.02+2.29 (+1.41%) ▲|TSLA372.15+18.04 (+5.09%) ▲|TXN293.57+12.26 (+4.36%) ▲|UBER68.09+0.21 (+0.31%) ▲|UNH369.92+4.72 (+1.29%) ▲|UNP277.47+5.05 (+1.85%) ▲|UPS93.22-0.67 (-0.71%) ▼|USB57.54+0.18 (+0.31%) ▲|V360.65+0.80 (+0.22%) ▲|VZ45.95-0.03 (-0.07%) ▼|WFC80.28+0.03 (+0.04%) ▲|WMT104.20-0.07 (-0.06%) ▼|XOM164.35+0.53 (+0.32%) ▲|
26.4 C
New York
Friday, October 2, 2026

Tag: source

GLP-1 Market Analysis Report 2025: How GLP-1a Trends Could Shape Future Food Strategies

Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, and nutrients. Discover insights, identified consumer groups, and actionable strategies for food companies.
Explore how GLP-1a drugs transform the food industry from a threat to an opportunity. Our 36-page strategy briefing outlines the potential for growth by meeting the rising demand for protein, fiber, and nutrients. Discover insights, identified consumer groups, and actionable strategies for food companies.

Síminn hf. – Reglubundin tilkynning um kaup á eigin bréfum í samræmi við endurkaupaáætlun

Í 31. viku 2025 keypti Síminn hf. 5.000.000 eigin hluti að kaupverði 67.900.000 kr. skv. sundurliðun hér á eftir:

Uzum Secures $70M Equity Financing Led by Tencent and VR Capital, Reaches $1.5B Valuation

Funding to accelerate the expansion of Uzbekistan's leading fintech platform and e-commerce ecosystem Uzum raises nearly $70 million in equity financing led by Tencent and...

Ecotec puts remote methane detection into pockets with the Gazoscan Mini

Ecotec’s Gazoscan Mini puts laser methane detection in every operator’s pocket. It's lightweight, rugged, and accurate up to 50 feet.

Guidehouse Research Estimates Global Market for Distributed Energy Resources Will Grow to 7.6 Million GW by 2033

Strong DER policies can help create market growth and ensure the grid can meet future demand BOULDER, Colo., Aug. 5, 2025 /PRNewswire/ -- A new report from...

World Intelligent Vehicle Conference 2025 Successfully Concludes

Writing a New Chapter for the Development of Intelligent Vehicles CHONGQING, China, Aug. 5, 2025 /PRNewswire/ -- World Intelligent Vehicle Conference (WIV) 2025 successfully...

Yum China Board Welcomes New Board Member

SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- Yum China Holdings, Inc. (the "Company" or "Yum China") (NYSE: YUMC and HKEX: 9987) announced today the appointment...

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.

GDS Announces Official Listing and Trading of its C-REIT on the Shanghai Stock Exchange from 8 August, 2025

SHANGHAI, China, Aug. 05, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that its previously announced China REIT (“C-REIT”) will be officially listed and start trading on the Shanghai Stock Exchange from 8 August, 2025, under the fund code 508060.

Accelerating Intelligent Education at APAN60 & Huawei Intelligent Education Forum 2025

HONG KONG, Aug. 5, 2025 /PRNewswire/ -- During the APAN60 held from July 28 to August 1, Huawei as a diamond sponsor, showcased its...

125,000+ hospitality staff now use Mews to deliver remarkable experiences

The modern, intuitive platform makes it easy for staff to delight guests and drive business success.  NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Mews, the industry-leading...

RESULT OF RIKSBANK CERTIFICATE SALE

AuctionAuction resultsAuction date2025-08-05Start date2025-08-06Maturity date2025-08-13Interest rate, %2.00Offered volume, SEK bn661.0Total bid amount, SEK bn546.1Accepted volume, SEK bn546.1Number of bids15Percentage allotted, %100.0 Source:...

Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management

Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector.
Endocarditis, a heart infection caused by bacteria in the bloodstream, is experiencing growing incidence due to rising healthcare-associated infections, intravenous drug use, and aging populations with prosthetic valves. Advances in diagnostic imaging, AI-assisted echocardiography, and minimally invasive cardiac procedures are improving detection and patient outcomes. However, challenges like early detection difficulties and antimicrobial resistance persist. North America leads in the endocarditis market, with significant growth seen in the Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in the sector.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSource